Products /
Biofourmis Therapeutics
Biofourmis Therapeutics
Overview
Contents
Select which hospital or health system you work at and see a personalized match score.
HELPFUL TOOLS
About
DESCRIPTION
Read more
Accelerating therapy innovation and clinical research with holistic, end-to-end solution to remotely capture and analyze continuous patient data utilizing FDA-cleared algorithms.
PRODUCT ATTRIBUTES
COVID-19
Pediatric
CLIENTS OVERVIEW
Key Clients
Clients Your Size
USED BY
0 People
10 Organizations
EHR integration
Integrations: | Not applicable |
EMR Integration & Relevant Hardware: | Use case dependent |
EMRs Supported: | Not applicable |
Hardware Compatibility: | Desktop, Mobile / Tablet (web optimized), Mobile / Tablet (native app) |
Description
Biofourmis Therapeutics accelerates therapy innovation and clinical research with its holistic, end-to-end solution to remotely capture and analyze continuous patient data utilizing FDA-cleared algorithms in clinical trial settings.
Use cases
Description
Development of Digital Therapeutics - Clinically validated software to treat and manage patients with unmet clinical needs. These digital therapies work independently or in conjunction with pharmacotherapies, augmenting drug efficacy, reducing costs, and driving better patient outcomes.
Decentralized Clinical Trials - Reduce clinical trial timelines and capture robust patient data in decentralized and virtual trials.
Commercialization and Market Access - Understand real world usage to improve outcomes and increase effectiveness of marketed therapies.
Users:
Differentiators
Differentiators vs EHR Functionality:
Differentiators vs Competitors:
End-To-End Solution - Biofourmis Therapeutics platform includes features such as telehealth, active ePRO and passive sensor data collection, a comprehensive patient kit and provisioning service, algorithm development, and digital clinical research services.
Device Agnostic Platform - The data platform can integrate with nearly any connected device, allowing for the identification and capture of novel patient-centric biomarkers.